Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.
武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

NOTICE OF THE EGM

NOTICE IS HEREBY GIVEN THAT the EGM of Wuhan YZY Biopharma Co., Ltd. (武漢友芝友生物製藥股份有限公司) (the "**Company**") will be held at Conference Room 3, 2nd Floor, Building C2–1, No. 666 Gaoxin Road, East Lake High Tech Development Zone, Wuhan, Hubei Province, PRC on Tuesday, 17 November 2026 at 10:00 a.m. for the purposes of considering and, if thought fit, passing the following resolutions:

SPECIAL RESOLUTIONS

1. "**THAT**:

   (a) the share subscription agreement (the "**Share Subscription Agreement**") dated 30 August 2026 entered into between the Company and Dr. Yuan Qian, Dr. Zhou Hongfeng and Dr. Zhou Pengfei (the "**Subscribers**") (a copy of which has been produced to this meeting marked "A" and signed by the chairman of this meeting for the purpose of identification) in relation to the subscription by the Subscribers of 35,592,400 new Domestic shares (the "**Subscription Share(s)**") of RMB1 each in the Company at the subscription price of RMB2.43 (equivalent to HK$2.80957) per Subscription Share (the "**Subscription**") and the transactions contemplated thereby be and are hereby approved, confirmed and ratified;

   (b) all the transactions contemplated under the Share Subscription Agreement, including but not limited to the specific mandate to allot and issue the Subscription Shares by the Company to the Subscribers pursuant to the Share Subscription Agreement (the "**Specific Mandate**"), be and are hereby approved and the Board be and is hereby authorised to allot and issue the Subscription Shares to the Subscribers pursuant to the Share Subscription Agreement; and

(c) any one executive Director(s) or its authorized person is authorised to implement and take all steps and to do acts and things which as he/she deems may be necessary or desirable to give effect and/or to complete or in connection with the Share Subscription and transactions contemplated thereunder, including but not limited to approving any changes or amendments thereto, to obtain all necessary approvals from, and making all relevant registrations and filings with, the relevant PRC and other authorities, and to sign and execute such further documents, or to doing any other things incidental thereto and/or as contemplated thereunder, and the abovementioned authorisation and resolutions regarding the Share Subscription and/or the issuance of Subscription Shares shall be valid for a period of 12 months from the date of approval by the Shareholders.''

2. **THAT** subject to the granting of the Whitewash Waiver (as defined below) by the Executive Director of the Corporate Finance Division of the Securities and Futures Commission of Hong Kong or any of his delegate(s) and any conditions that may be imposed thereon, the waiver (the ''**Whitewash Waiver**'') of the obligation on the part of the Subscribers to make a mandatory general offer for all the issued shares and other securities of the Company (other than those already owned or agreed to be acquired by the Subscribers or the Concert Parties) which might otherwise arise as a result of the Subscribers subscribing for the Subscription Shares under the Share Subscription Agreement pursuant to Note 1 on dispensations from Rule 26 of the Takeovers Code be and is hereby approved, and that any one or more of the Directors be and is/are hereby authorised to do all such acts and things and execute all such documents under seal where applicable as he considers necessary, desirable or expedient for the purpose of, or in connection with, the implementation of and giving effect to any of the matters relating to, or incidental to, the Whitewash Waiver.

3. **THAT** the Board and its authorized person(s) be and is/are hereby authorised to change the registered capital and amend relevant provisions of the existing articles of association of the Company correspondingly upon the completion of the Share Subscription.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
Chairman of the Board, Executive Director and Chief Executive Officer

Wuhan, PRC, 30 October 2026

Notes:

1. Details of the above resolutions are set out in the circular of the Company dated 30 October 2026 (the ''**Circular**''). Unless the context otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Circular.

2. All resolutions at the meeting will be taken by poll pursuant to the Listing Rules and the Articles of Association. The results of the poll will be published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.yzybio.com) in accordance with the Listing Rules.

3. Any Shareholder entitled to attend and vote at the meeting is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy needs not be a Shareholder. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every Shareholder present in person or by proxy shall be entitled to one vote for each share held by him/her.

4. The form of proxy shall be signed by the Shareholder or his/her/its attorney who has been authorized in writing. If the Shareholder is a corporation, the form of proxy shall be affixed with the corporation's seal or signed by its director, or its attorney duly authorized in writing. If the form of proxy is signed by the attorney of the Shareholder, the power of attorney or other authorization document shall be notarized. For Shareholders, the aforementioned documents must be deposited at the Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M/F, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong not less than 24 hours before the time appointed for the meeting (i.e. not later than 10:00 a.m. on Monday, 16 November 2026) or the adjourned meeting (as the case may be). Completion and return of the form of proxy shall not preclude a Shareholder from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.

5. An individual Shareholder shall produce his/her identification document when attending the EGM.

6. A proxy who attends the EGM upon entrustment by a Shareholder should produce his/her identification document and the power of attorney issued by the Shareholder. If a representative of a corporate Shareholder attends the EGM, such representative shall produce his/her identification document and the notarized copy of the power of attorney or other notarized copy of any authorization documents issued by such corporate Shareholder.

7. In order to determine the entitlement of H Shareholders to attend and vote at the EGM, the register of members of the Company will be closed from Thursday, 12 November 2026 to Tuesday, 17 November 2026 (both days inclusive), during which period no transfer of shares in the Company will be registered. In order to qualify for attending and voting at the forthcoming EGM, all transfer forms accompanied by the relevant share certificates must be lodged with the Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, for registration not later than 4:30 p.m. on Wednesday, 11 November 2026.

8. H Shareholders of the Company whose names appear on the register of members of the Company at the close of business on Tuesday, 17 November 2026, being the record date, are entitled to attend and vote at the EGM or any adjourned meetings.

9. The contact of the Company:

Address	:	Board Office Wuhan YZY Biopharma Co., Ltd. (武漢友芝友生物製藥股份有限公司) No. 666 Gaoxin Road East Lake High Tech Development Zone Wuhan, Hubei Province PRC
Postal Code	:	430075
Tel	:	(86) 027–82668988
Contact Person	:	Mr. Zheng Jianhua
Email	:	zhengjianhua@yzybio.com

10. References to time and dates in this notice are to Hong Kong time and dates.

As at the date of this notice, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive Directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive Directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.